NeuroPace Inc

NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System. The company designs, manufactures, and sells a brain-responsive neuromodulation platform that monitors electrical activity in the brain and delivers targeted stimulation at the seizure source.

−16,1 %

77,2 %

−21,5 %

+25,1 %

5.28

4.33

— NeuroPace Inc
%
RNS System85% Implantable brain-responsive neuromodulation devices and related therapy for epilepsy.
Replacement procedures8% Sales tied to replacement of implanted RNS devices at end of service life.
DIXI Medical products5% Adjunct epilepsy-related products sold to the existing customer base during wind-down.
Services and collaboration revenue2% Service revenue and collaboration-related services, including work for partners.

NeuroPace sells primarily to hospital facilities that implant the RNS System for patients with drug-resistant epilepsy...

  • Hospital facilitiesprimary

    Buy RNS Systems for initial implants and replacement procedures for eligible epilepsy patients.

  • Comprehensive epilepsy centersprimary

    Evaluate, refer, and implant patients; they are the main channel for adoption and utilization.

  • Physicians and specialistsprimary

    Epileptologists and neurosurgeons influence prescribing, implantation, and follow-up care.

  • Existing installed basesecondary

    Patients returning for replacement procedures as devices reach end of service.

  • Partner customersemerging

    Counterparties receiving collaboration services and limited DIXI-related products.

NeuroPace is primarily a U.S. business, with nearly all revenue generated in the United States...

  • •United States is the core commercial market
  • •Nearly all revenue is generated in the U.S.
  • •Limited sales in Canada under special approvals
  • •Manufacturing and distribution are based in Mountain View, California
  • •U.S. epilepsy centers drive most commercial activity

NeuroPace is focused on expanding adoption of the RNS System across comprehensive epilepsy centers and broader referral...

01
Expand U.S. commercial footprintshort-term

Adoption depends on physician awareness, referrals, and center-level penetration.

02
Pursue indication expansionmedium-term

Broader labels can enlarge the addressable epilepsy population and support long-term growth.

03
Build clinical evidence and data advantagemedium-term

Long-term outcomes and continuous brain data support physician adoption and differentiation.

04
Develop future neuromodulation productslong-term

New products can extend the platform beyond the current epilepsy indication.

NeuroPace depends heavily on a single commercial product and a narrow U.S. epilepsy indication, so adoption,...

high

Dependence on a single product and indication

Most revenue comes from the RNS System for adults with drug-resistant focal epilepsy.

Scope
U.S. epilepsy market
Materiality
high
high

Competitive pressure from larger device makers

LivaNova and Medtronic have greater scale, resources, and market presence.

Scope
Neuromodulation therapies
Materiality
high
high

Regulatory and clinical adoption risk

Growth depends on FDA approvals, clinical evidence, and physician acceptance.

Scope
Indication expansion and new center adoption
Materiality
high
medium

Manufacturing and supply continuity

Devices are manufactured and distributed from a single California facility.

Scope
Mountain View operations
Materiality
medium
medium

Cybersecurity and patient-data privacy

The business handles sensitive health data and relies on connected systems and third parties.

Scope
Remote monitoring and cloud/IT systems
Materiality
medium
Revenue recognition by product and service type
Affects quarterly revenue comparability and mix analysis
Product mix and replacement cycle
Can create quarter-to-quarter variability in revenue and gross margin
Inventory excess and obsolescence reserves
Can materially affect cost of goods sold and gross profit
Stock-based compensation and financing transactions
Affects operating expense presentation and dilution analysis

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

INTERPACE BIOSCIENCES, INC.

IDXG · Surgical & Medical Instruments & Apparatus

Neuronetics, Inc.

STIM · Surgical & Medical Instruments & Apparatus

NEUROONE MEDICAL TECHNOLOGIES Corp

NMTC · Surgical & Medical Instruments & Apparatus

electroCore, Inc.

ECOR · Electromedical & Electrotherapeutic Apparatus

NEUROCRINE BIOSCIENCES INC

NBIX · Biological Products, (No Diagnostic Substances)

: 29.4.2026